|
Oncology NEWS International. Vol. 11 No. 7 Study to Measure Impact of ProstaScint Imaging in Prostate Cancer
July 1, 2002
PRINCETON, New Jersey—Cytogen Corporation’s ProstaScint (capromab
pendetide) is being evaluated in a phase I/II clinical study for its utility in
helping guide intensity modulated radiation therapy (IMRT) for prostate cancer.
ProstaScint is a radiolabeled monoclonal antibody that targets prostate specific
membrane antigen. In the study, the specific areas of greatest tumor burden
within the prostate, identified by the ProstaScint image, will receive boosted
doses of radiation via IMRT. |
FROM PHYSICIANS PRACTICE
Five Steps to Improving Patient Access Judy Capko, May 21, 2013 Patient access is getting increased attention through reform initiatives. Here are five steps you can take to make sure patients get appropriate access to care in your office. Growing HIPAA Threat – Ignore Windows XP at Your Own Peril Marion K. Jenkins, May 21, 2013 Chances are good that you have some major ticking software time bombs lurking in your medical practice's computer environment, namely Windows XP and Server 2003. Finding Physician Work-Life Balance in the Small Moments Jennifer Frank, MD, May 21, 2013 At my practice and at home, things are always busy. There's laundry or homework, or a patient with needs. Three Areas to Reduce Costs at Your Medical Practice Greg Mertz, May 19, 2013 By taking a hard look at reducing costs for staffing, overhead, and technology at your medical practice, you may see increased physician compensation. Dos and Don’ts for Starting a Physician Blog Michael Woo-Ming, MD, May 18, 2013 Starting a physician blog can provide your medical practice with marketing benefits, but it's important to do it right.
CancerNetwork on Facebook
|
© 1996 - 2013 UBM Medica LLC, a
UBM company
Privacy Statement -
Terms of Service -
Advertising Information -
Editorial Policy Statement -
UBM Medica Network Privacy Policy
